Drug discovery > Lead Discovery Products & Reviews

Bioinformatics and Protein Array Services

Profiling against cancer antigens. Using the CTA Protein Array, Sengenics can quantify autoantibodies against more than 200 clinically relevant cancer testis antigens. These are tumor antigens normally expressed in germ cells but not in adult somatic tissues. In cancers, this regulation can be disrupted, resulting in CTA expression in tumors. The CTA array is ideal for research related to cancer immunotherapy.

Cancer drug screening and discovery. The OncoRex p53 Cancer Array provides a biologically relevant screening tool since all p53 variants are correctly folded and functional using the patented KREX ® protein folding technology. Using the array, Sengenics can screen your therapeutic antibodies and protein binding compounds against more than 100 p53 wildtype and mutant variants by measuring their impact on DNA binding as a func…

The i-Ome Discovery Protein Array uses the patented KREX® protein folding technology to enable accurate and reproducible profiling of patient samples against more than 1800 carefully selected full-length, properly folded proteins. Curated content focused on known and potential autoantigens helps facilitate biomarker discovery with significantly lower false discovery rates and smaller sample sizes than other technologies. The…

Autoimmune disease autoantibody screening. Using the Pan-Autoimmune Protein Array 1.0, Sengenics can screen autoantibodies against more than 100 clinically relevant antigens in a wide range of autoimmune diseases. The Pan-Autoimmune Protein Array 1.0 service is ideal for focused autoimmune disease research.